布地奈德联合复方异丙托溴铵雾化吸入治疗肺炎支原体感染后慢性咳嗽的临床效果

Clinical Effect of Nebulization Inhalation of Budesonide and Compound Ipratropium Bromide in Treatment of Chronic Cough after Mycoplasma Pneumoniae Infection

目的探讨布地奈德联合复方异丙托溴铵雾化吸入治疗肺炎支原体感染后慢性咳嗽的临床效果。方法选取2018年3月至12月舒兰市人民医院呼吸内科治疗的56例肺炎支原体感染后慢性咳嗽患者随机分为两组,对照组单用复方异丙托溴铵雾化吸入治疗,观察组使用布地奈德联合复方异丙托溴铵雾化吸入治疗。比较两组患者的临床疗效、咳嗽症状评分、血嗜酸粒细胞阳离子蛋白(ECP)和嗜酸性粒细胞(EOS)水平。结果观察组治疗有效率明显高于对照组(96.43%vs.75.00%,P<0.05);观察组治疗3、5、7 d后的咳嗽症状评分明显低于对照组(P<0.05);观察组治疗后2个月的ECP和EOS水平明显低于对照组(P<0.05)。结论布地奈德联合复方异丙托溴铵雾化吸入治疗肺炎支原体感染后慢性咳嗽的疗效显著,能有效缓解咳嗽症状,降低炎性因子水平,抑制咳嗽复发。

Objective To evaluate the clinical effect of atomization inhalation of budesonide and compound ipratropium bromide on chronic cough after mycoplasma pneumoniae infection.Methods Fifty-six patients with chronic cough after infection with mycoplasma pneumoniae were randomly divided into two groups,who were treated in our respiratory department from March to December 2018.The control group was treated with compound ipratropium bromide atomization inhalation alone.The observation group was treated with budesonide and compound ipratropium bromide atomization inhalation.The clinical efficacy,the cough symptoms scores and the levels of ECP and EOS were compared between the two groups.Results The effective rate of treatment in the observation group was significantly higher than that in the control group(96.43%vs.75.00%,P<0.05).The scores of cough symptoms in the observation group were significantly lower than those in the control group at 3,5 and 7 d after treatment(P<0.05).The levels of ECP and EOS in the observation group were significantly lower than those in the control group 2 months after treatment(P<0.05).Conclusion Budesonide and compound ipratropium bromide atomization inhalation in the treatment of chronic cough after mycoplasma pneumoniae infection can effectively relieve cough symptoms,reduce the level of inflammatory factors.